NCT03406949: MGD009/MGA012 Combination in Relapsed/Refractory Cancer

NCT03406949
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have B7-H3 expression on tumor cells
Exclusions: 
https://ClinicalTrials.gov/show/NCT03406949

Comments are closed.

Up ↑